We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Attractin Mediates Invasiveness of Certain Brain Tumors

By Biotechdaily staff writers
Posted on 01 Dec 2006
Cancer researchers have found that the protein attractin, which is produced by cells present in certain types of brain tumors, is an important mediator of tumor invasiveness and a reliable biomarker for the detection of malignant astrocytoma.

Investigators at Emory University (Atlanta, GA, USA) used advanced proteomic techniques to analyze cerebrospinal fluid (CSF) or cyst fluid samples from 60 patients with various diseases of the central nervous system. They found that attractin was consistently elevated in the samples from patients with malignant astrocytoma, a common and highly aggressive type of brain cancer.

To independently validate these results, they examined attractin expression in a new set of 108 normal and tumoral brain tissue specimens and found elevated expression in 97% of malignant astrocytomas, with the highest levels found in grade four tumors. Immunohistochemical data published in the November 2006 issue of Clinical Cancer Research showed that attractin was produced and secreted by the tumor cells. Furthermore, cerebrospinal fluid from brain tumor patients induced glioma cell migration, and attractin was largely responsible for this promigratory activity.

"Using proteomic analyses of the CSF of patients with brain tumors, we have identified for the first time that attractin levels are elevated in patients with high-grade astrocytoma,” said senior author Dr. Erwin Van Meir, professor of neurosurgery and hematology/oncology at Emory University. "Because few noninvasive methods are available for monitoring CNS malignancies, there is an urgent need to find reliable indicators. Our studies suggest that measuring attractin levels in patients with grades II-IV astrocytoma should be explored further as a potential biomarker for monitoring the growth of these tumors or as a potential new target for therapy.”



Related Links:
Emory University

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automated Urinalysis Solution
UN-9000

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
01 Dec 2006  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
01 Dec 2006  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
01 Dec 2006  |   BioResearch